血液中の人々の関節健康を評価する長期研究は
血液症a(高度)のある人の共同健康に関するエファネソクトコグALFAによる実世界の予防的治療の長期的な有効性を評価するための低介在性研究
The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.
調査の概要
詳細な説明
This is a retrospective-prospective, low-interventional study to evaluate the long-term effectiveness of real-world prophylaxis with efanesoctocog alfa on joint health in people with haemophilia A. Participants in the study must be prescribed efanesoctocog alfa at the discretion of their physicians within 6 months prior to, or at the time of, enrolment. The decision to initiate treatment with efanesoctocog alfa shall be made independently from the decision to include the patients in the study. A broad haemophilia A population (e.g. all severities [mild to severe], all ages, patients with comorbidities and/or concomitant use of anticoagulant/antiplatelet drugs, patients with previous inhibitors to Factor FVIII [FVIII]) will be eligible to enrol. The study will require mandatory on-site visits with joint assessments. A retrospective data collection on patients' haemophilia, medical, and surgical history will be performed, including previous haemophilia treatment and treated bleeding episodes from 12 months prior to initiating treatment with efanesoctocog alfa until enrolment.
The study will start with the enrolment visit during a patient's routine visit to the hospital, to check whether the patient fulfils all the inclusion criteria and none of the exclusion criteria. Study participants will have yearly on-site visits for 24 months or 36 months, depending on the time of enrolment in relation to study closure. Patients will be followed in the study as long as they are treated with efanesoctocog alfa prophylaxis which would be at the physicians' discretion. Patients will also need to agree to document any bleeding episodes they may have during the study in a study-specific paper diary. Joint assessment, Haemophilia Joint Health Score (HJHS), and completion of Patient-reported outcomes (PROs) will be conducted during the on-site visits. For patients included in the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) group, ultrasound joint assessment will also be done at the yearly visits. The end of study (EoS) visit can be performed at the 24-month visit or the 36-month visit, depending on the time of enrolment.
The target is to enroll approximately 250 participants.
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Dublin、アイルランド
- Sobi Investigational Site
-
-
-
-
-
Birmingham、イギリス
- Sobi Investigational Site
-
Cardiff、イギリス
- Sobi Investigational Site
-
London、イギリス
- Sobi Investigational Site
-
Manchester、イギリス
- Sobi Investigational Site
-
-
-
-
-
Catania、イタリア
- Sobi Investigational Site
-
Padua、イタリア
- Sobi Investigational Site
-
Salerno、イタリア
- Sobi Investigational Site
-
Turin、イタリア
- Sobi Investigational Site
-
-
-
-
-
Zagreb、クロアチア
- Sobi Investigational Site
-
-
-
-
-
A Coruña、スペイン
- Sobi Investigational Site
-
Barcelona、スペイン
- Sobi Investigational Site
-
Málaga、スペイン
- Sobi Investigational Site
-
Palma de Mallorca、スペイン
- Sobi Investigational Site
-
Zaragoza、スペイン
- Sobi Investigational Site
-
-
Castille and León
-
Salamanca、Castille and León、スペイン
- Sobi Investigational Site
-
-
-
-
-
Brno、チェコ
- Sobi Investigational Site
-
Ostrava、チェコ
- Sobi Investigational Site
-
Prague、チェコ
- Sobi Investigational Site
-
-
-
-
-
Berlin、ドイツ
- Sobi Investigational Site
-
Bonn、ドイツ
- Sobi Investigational Site
-
Frankfurt am Main、ドイツ
- Sobi Investigational Site
-
Hamburg、ドイツ
- Sobi Investigational Site
-
Munich、ドイツ
- Sobi Investigational Site
-
-
-
-
-
Bordeaux、フランス
- Sobi Investigational Site
-
Marseille、フランス
- Sobi Investigational Site
-
Montpellier、フランス
- Sobi Investigational Site
-
Nantes、フランス
- Sobi Investigational Site
-
Paris、フランス
- Sobi Investigational Site
-
Rennes、フランス
- Sobi Investigational Site
-
Rouen、フランス
- Sobi Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female patient with a diagnosis of haemophilia A.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Prescribed with efanesoctocog alfa prophylactic treatment within 6 months prior to study enrolment or at the latest at the enrolment visit, in accordance with local regulations.
- Must have received prophylactic treatment(s) with any haemophilia product(s) for at least 12 months prior to being prescribed with efanesoctocog alfa treatment.
- Have documented pre-study treatment data on haemophilia prophylaxis prescriptions and on treated bleeding episodes from the 12-months prior to being prescribed efanesoctocog alfa treatment and until enrolment into this study.
- Willing to adhere to the visit schedule and to undergo mandatory study assessment (HJHS, PROs).
- Willingness and the ability of the patient or their legally designated representative to document all bleeding episodes, including any treatments for those episodes.
- For HEAD-US subgroup: Accept to undergo annual ultrasound assessment on the index joints (ankles, elbows, knees).
Exclusion Criteria:
- Acquired haemophilia A and other blood clotting disorders than hereditary haemophilia A.
- Any positive FVIII inhibitor result (defined as inhibitor titre ≥0.6 Bethesda unit [BU]/mL) from the medical records in connection to the switch to efanesoctocog alfa until the enrolment visit.
- Enrolment in a concurrent clinical interventional study, or intake of an investigational medicinal product (IMP), including for haemophilia prophylaxis, within 3 months prior to enrolment in this study.
- Patient not suitable for participation, whatever the reason, as judged by the Investigator, e.g., patient is not able or willing to perform the study assessments.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:研究治療グループ
|
Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
将来の観察期間にわたる年間関節出血率(AJBR)。
時間枠:12、24、36か月への登録
|
12、24、36か月への登録
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
将来の観察期間にわたる年間出血率(ABR)。
時間枠:12、24、36か月への登録
|
12、24、36か月への登録
|
|
|
将来の観察期間中に出血イベントを制御するための注射の数。
時間枠:12、24、36か月への登録
|
12、24、36か月への登録
|
|
|
将来の観察期間にわたる年間注入頻度。
時間枠:12、24、36か月
|
12、24、36か月
|
|
|
前向き観察期間にわたって、予防と出血の治療(手術を除く)のための年間エファネソクトコグALFA消費。
時間枠:12、24、36か月
|
12、24、36か月
|
|
|
前向き観察期間におけるエファネソクトコグアルファ予防の規定の頻度および/または用量の変化の理由。
時間枠:12、24、36か月への登録
|
12、24、36か月への登録
|
|
|
Efanesoctocog alfa vs以前の血液症治療を使用する期間のABRの変化。
時間枠:将来の期間と遡及的期間
|
将来の期間と遡及的期間
|
|
|
Efanesoctocog Alfaの期間中の年間注入頻度の変化対以前の血液治療の期間。
時間枠:将来の期間と遡及的期間
|
将来の期間と遡及的期間
|
|
|
Efanesoctocog Alfaの期間中の年間消費の変化対以前の血液治療の期間。
時間枠:将来の期間と遡及的期間
|
将来の期間と遡及的期間
|
|
|
Efanesoctocog Alfa治療に切り替える理由。
時間枠:レトロスペクティブ期間(登録の12〜18か月前)
|
レトロスペクティブ期間(登録の12〜18か月前)
|
|
|
血栓症および血液症(ISTH)に関する国際社会に対する患者の止血反応の調査員または外科医の評価は、外科的処置スケール(術中および術後)の4点反応。
時間枠:手術後96時間以内
|
手術後96時間以内
|
|
|
マイナーおよび主要な手術のために周術期に止血を維持するために投与される注射および用量の数。
時間枠:36か月への登録
|
36か月への登録
|
|
|
マイナー/主要な手術の周術期間中の総efanesoctocog ALFA消費。
時間枠:36か月への登録
|
36か月への登録
|
|
|
治療選好調査
時間枠:12か月目
|
12か月目
|
|
|
深刻な有害事象(SAE)が発生した参加者の数。
時間枠:36か月への登録
|
36か月への登録
|
|
|
特別な関心のある有害事象が発生した参加者の数(Aesis)。
時間枠:36か月への登録
|
36か月への登録
|
|
|
Total dose to control bleeding event over the prospective observation period.
時間枠:Enrolment to Month 12, 24 and 36
|
Cumulative amount of medication administered to effectively manage bleeding episodes. |
Enrolment to Month 12, 24 and 36
|
|
Haemophilia Joint Health Score (HJHS) version 2.1
時間枠:Enrolment to Month 12, 24 and 36
|
Change from enrolment in total and domain scores of HJHS per patient. |
Enrolment to Month 12, 24 and 36
|
|
Target joint development on a patient and joint level over the prospective observation period.
時間枠:Month 12, 24 and 36
|
A target joint is defined as joints with 3 or more spontaneous bleeding episodes within a consecutive 6-month period. |
Month 12, 24 and 36
|
|
Target joint resolution on a patient and joint level over the prospective observation period.
時間枠:Month 12, 24 and 36
|
A target joint is defined as joints with 3 or more spontaneous bleeding episodes within a consecutive 6-month period. |
Month 12, 24 and 36
|
|
Target joint recurrency on a patient and joint level over the prospective observation period.
時間枠:Month 12, 24 and 36
|
A target joint is defined as joints with 3 or more spontaneous bleeding episodes within a consecutive 6-month period. |
Month 12, 24 and 36
|
|
Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)
時間枠:Enrolment to Month 12, 24 and 36
|
Change from enrolment in total and domain score. |
Enrolment to Month 12, 24 and 36
|
|
Patient Reported Outcome (PRO) of Pain Intensity
時間枠:Enrolment to Month 12, 24 and 36
|
Use of PROMIS SF v2.0 to measure change in patient-reported pain intensity from enrolment. |
Enrolment to Month 12, 24 and 36
|
|
Patient Reported Outcome (PRO) of Pain Interference
時間枠:Enrolment to Month 12, 24 and 36
|
Use of PROMIS SF v2.0 to measure change in patient-reported pain interference from enrolment. |
Enrolment to Month 12, 24 and 36
|
|
Patient Reported Outcome of 5-level EuroQol-5 dimensions [EQ-5D-5L] score
時間枠:Enrolment to Month 12, 24 and 36
|
Changes from enrolment of patient mobility, self-care, usual activities, pain/discomfort, anxiety/depression. |
Enrolment to Month 12, 24 and 36
|
|
Patient Reported Outcome of youth EuroQol 5-dimensions [EQ-5D-Y] score
時間枠:Enrolment to Month 12, 24 and 36
|
Changes from enrolment of patient mobility, self-care, usual activities, pain/discomfort, anxiety/depression using child-appropriate wording. |
Enrolment to Month 12, 24 and 36
|
|
Patient Reported Outcome of Parent Proxy EuroQol 5-dimensions [EQ-5D-Y:1] score
時間枠:Enrolment to Month 12, 24 and 36
|
Parent or caregiver's rating of the child's health outcomes based on mobility, self-care, usual activities, pain/discomfort, anxiety/depression. |
Enrolment to Month 12, 24 and 36
|
|
Patient Reported Outcome of ACTIVLIM-Hemo.
時間枠:Enrolment to Month 12, 24 and 36
|
Measurement of activity limitations for patients with haemophilia (PwH). |
Enrolment to Month 12, 24 and 36
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディディレクター:Study Physician、Swedish Orphan Biovitrum AB (publ)
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Sobi.BIVV001-005
- 2024-517812-31-00 (Ctis)
- U1111-1312-9668 (レジストリ識別子:WHO Universal trial number (UTN))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents. Patient level data will be anonymized and study documents, if applicable will be redacted to protect the privacy of trial participants.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。